Table 1. Treatments given as first-line in three randomized trials.

*This should be assumed to be positivity of ≥1%. **Reference [5] also reports the overall survival determined in the population with CPS≥10% that included 220 patients given pembrolizumab and 103 controls; events were 155 and 84, respectively. Abbreviations: n, number of events; N, the total number of patients; RMST, restricted mean survival time; CPS, Combined Positive Score.

Trial	First author, year of publication	PD(L)1 positivity	Treatment group (n/N)	Control group (n/N)	Survival curve reported in the original publication
IM-PASSION-130	Emens, 2021 [6]	PD-L1 positive population*	Atezolizumab plus nab-paclitaxel (120/185)	Placebo plus nab-paclitaxel (139/184)	Figure 1B
IM-PASSION-131	Miles, 2021 [7]	PD-L1 positive population*	Atezolizumab plus paclitaxel (72/191)	Paclitaxel (51/101)	Figure 3A
KEYNOTE-355	Rugo, 2021** [5]	CPS≥1%	Pembrolizumab plus chemotherapy (336/425)	Chemotherapy (177/211)	URL on the Internet (see [5])